Protein Found to Drive Colorectal Cancer Growth
Researchers identified LRP6 as a key promoter of cancer in the Wnt/beta-catenin and STAT3 signaling pathways.
Updated on Oct. 29, 2026 in Cancer
Live Poll
Does this discovery make you more optimistic about future medical treatments for colorectal cancer?
Scientists have discovered that the LRP6 protein plays a critical role in promoting colitis-associated colorectal cancer. The research highlights how this protein coordinates signaling pathways to fuel tumor progression.
Why it matters
Understanding the function of LRP6 provides a potential target for therapeutic intervention in colorectal cancer. By blocking this protein, researchers hope to inhibit the pathways that drive tumor growth in the intestines.
Researchers identified that LRP6 promotes ALK-mediated STAT3 Y705 phosphorylation within intestinal epithelial cells. This mechanism was confirmed through BioID-mass spectrometry which mapped LRP6 interactions with STAT3 and ALK.
The players
LRP6
This protein acts as a co-receptor in the Wnt/beta-catenin signaling pathway and serves as a promoter of colitis-associated colorectal cancer.
6-thioguanine
This chemical compound was found to suppress LRP6 function by inducing the lysosomal degradation of the protein.
The details
The study found that DSS increases LRP6 levels in intestinal cells, and LRP6-deficient crypts show impaired formation capacity. Experiments demonstrated that 6-thioguanine binds to the LRP6 intracellular domain, inducing lysosomal degradation and suppressing tumor growth in mouse models.
Timeline
October 29, 2026: The research findings were published.
The Big Picture
This study refines our understanding of the Wnt/beta-catenin signaling pathway by defining the specific regulatory role of LRP6 in colorectal cancer. The discovery bridges the gap between molecular interactions and tumor progression, providing a new target for future oncological research.
This discovery identifies LRP6 as a potential therapeutic target, which may eventually lead to new drug treatments for colorectal cancer patients. While the research is currently limited to laboratory models, it offers a new pathway for developing future clinical interventions.
The takeaway
Targeting the LRP6 protein represents a promising strategy for managing colorectal cancer growth. Scientists aim to leverage this molecular insight to inhibit tumor progression pathways effectively.
Further reading
For more information on current oncological research, visit the Cancer section.
More information
View the complete peer-reviewed research article on the Nature platform.
Source note: This article includes information reported by Nature.
Live Poll
Does this discovery make you more optimistic about future medical treatments for colorectal cancer?
